BioBlog

This week’s Innovation Partners BioBlog takes a look at several important stories. California Governor Newsom announced a plan to work with generic drug makers to lower costs of medications for residents. New therapies for ovarian cancer and high cholesterol are in the works. A look at the potential

You’ve heard the expression “all things old are new again” and it applies to cancer therapies, too. Drug developers are testing antibody-drug conjugates again. German manufacturer Boehringer has been clear to manufacture drugs in China, passing Chinese regulatory hurdles. The ACA is in the spotlight

Happy New Year! In this issue of the Innovation Partners BioBlog, we focus on the five top stories to watch in 2020 plus updates on new breast cancer treatments. Surprise billing, high drug prices, and the debate over Obama Care continue to lead news coverage for the health industry. Read more in

Happy New Year! We wish everyone a happy, healthy, and prosperous New Year. Here’s to a wonderful 2020! In this week’s Innovation Partners BioBlog, we update a few of 2019’s top stories regarding the ACA and proposals to lower the cost of prescription drugs. A new partnership between

Happy Holidays from Innovation Partners! We hope everyone has a lovely holiday and a Happy New Year. We’re heading into an election year, and that means that several bills on Capitol Hill may be stalled until after November. Lobbyists continue to meet with lawmakers about Nancy Pelosi’s drug pricing

This week, cancer treatment and care are in the spotlight in the Innovation Partners BioBlog. Treatment for AML and new drugs to target various cancers are in the news in addition to the price transparency rule and findings related to Medicare charges. Read on for more in this week's Innovation

This week's Innovation Partners BioBlog focuses on moves that drug companies are making both here and abroad. Canada pushed back at President Trump's plans to import drugs from Canada. Novartis plans to open a gene cell therapy manufacturing plant in Stein, Switzerland, to eliminate costly and

The pushback continues against the impending enactment in 2020 of a tax on medical devices, part of the Affordable Care Act legislation that's been delayed for ten years. Humana reports favorable results with its Medicare Advantage plans and provides evidence that it both saves money and improves